Chapter 5 162 Supplementary Table S3. Sensitivity analysis of adjusted odds ratios for severe fatigue at six months after illness onset: a) restricted to prospectively-enrolled participants only and b) outcome redefined as chronic fatigue Table S3a. Restricted to prospectively-enrolled participants only Model 1 Model 2 Model 3 aOR (95% CI) p-value aOR (95% CI) p-value aOR (95% CI) p-value Age per 10 year increase, years 1.00 (0.80-1.25) 0.970 0.99 (0.80-1.23) 0.903 0.94 (0.75-1.18) 0.802 Sex 0.405 0.334 0.564 Male Ref. Ref. Ref. Female 1.34 (0.71-2.53) 1.36 (0.72-2.570 1.24 (0.64-2.41) No. of highrisk COVID-19 comorbidities* 0.055 NA NA 0 Ref. NA NA 1 1.36 (0.62-3.01) NA NA 2 1.17 (0.40-3.48) NA NA 3+ 3.72 (1.20-11.60) NA NA COVID-19 clinical severity** NA 0.008 0.010 Mild NA Ref. Ref. Moderate NA 2.25 (1.04-4.84) 1.83 (0.82-4.08) Severe/critical NA 3.54 (1.36-9.19) 3.57 (1.32-9.56) Highest baseline sadness score*** NA NA 0.013 0-1 NA NA Ref. 2-5 NA NA 1.01 (0.45-2.29) 6-10 NA NA 2.76 (1.25-6.08) NA=Not applicable; RR=respiratory rate; SpO2= oxygen saturation. *COVID-related comorbidities are based on WHO Clinical Management Guidelines[16] and include: cardiovascular disease (including hypertension), chronic pulmonary disease (excluding asthma), renal disease, liver disease, cancer, immunosuppression (excluding HIV, including previous organ transplantation), previous psychiatric illness and dementia. **COVID-19 clinical severity groups defined as: mild as having a RR<20/min and SpO2 on room air >94% at both day 0 and 7; moderate disease as having a RR 20-30/min, SpO2 90-94% and/or receiving oxygen therapy at day 0 or 7; severe disease as having a RR>30/min or SpO2< 90% at day 0 or 7; critical disease as requiring ICU admission. ***Highest baseline sadness scores defined as the highest reported level of sadness at D0 and D7 (baseline), subjectively reported on a scale from 0 to 10.
RkJQdWJsaXNoZXIy MTk4NDMw